Fisher Funds’ New Zealand Growth Fund reversed its sterling performance in 2007 with a shocker in its most recent financial year.
Unit holders in the Growth Fund were sent a copy of the fund’s annual report last week, showing the value of their holdings has dropped 33.7 per cent: total unit holder’s funds declined by $46.3 million to just under $91 million in the year to March 31.
This was on the back of the hammering that small to medium sized New Zealand growth equity stocks took in the last six months of the fund’s financial year.
The fair value of the Growth Fund’s financial assets dropped from $156.8 million to $98.9 million, with its poorest investment performers being Pumpkin Patch, Metlifecare and Ryman Healthcare, its most heavily-weighted stock.
The Growth Fund’s equity selections are almost identical to that of Fisher Fund’s listed growth fund Kingfish; and the New Zealand investments included in its Kiwisaver scheme.
Unsurprisingly, Growth Fund unit holders did not pay any performance fees for the year; last year, Fisher Funds Management received a $1.7 million bonus for its successful stock picking.
At balance date, the Growth Fund’s unit price was $3.1527; it has since recovered slightly to $3.1761.
Fisher Funds celebrated its tenth anniversary this month.
This article is tagged with the following keywords. Find out more about MyNBR Tags
Most listened to
- Paul Brislen discusses the 'snake oil' sales tactics of SalesConcepts
- Fonterra chief executive Theo Spierings reveals his ambitious China plan
- UDC Finance chief executive Wayne Percival talks about the company's profit
- Hamish McNicol discusses the latest court stories
- Trilogy International CEO Angela Buglass reviews another bumper result
- Eroad CEO Steven Newman talks about his company's revenue increase
- What do the latest terrorism attacks in Mali and Israel mean? Nathan Smith discusses the latest foreign affairs news
- NZ Windfarms departing director Michael Stiassny speaks out after board exit
- James Mayo talks about SOS Hydration's growth plans after Snowball offer
- Michael Wood on whether he would run in Mt Roskill
- SAFE's Abi Izzard quizzed over protest of a caged hen operation at Pukekohe
- Nevil Gibson talks about Editor's Insight on the planned $US150 million merger between Pfizer and Allergan